About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Study Offers New Guidelines for Treating Rheumatoid Arthritis

by VR Sreeraman on July 24, 2008 at 4:16 PM
 Study Offers New Guidelines for Treating Rheumatoid Arthritis

Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology.

Lead author Kenneth Saag, M.D., M.Sc., a professor in the UAB Division of Clinical Immunology and Rheumatology, said the new guidelines update strategies for treating RA with the goal of preventing joint damage and disability.

Advertisement

The new recommendations do not strive to replace individualized medical decisions, Saag said. Instead, they are meant to guide rheumatologists and other health care workers toward the most updated recommendations. The last set of American College of Rheumatology RA treatment guidelines was published in 2002.

"The recommendations developed are not intended to be used in a 'cookbook' or prescriptive manner, or to limit a physician's clinical judgment," Saag said. "They provide guidance based on clinical evidence and expert panel input."
Advertisement

The recommendations focus on several classes of anti-arthritic drugs, including a potent group of agents called disease-modifying anti-rheumatic drugs (DMARDs). Newer genetically engineered DMARDs called biologics often work in combination with earlier therapies. Many anti-arthritic drugs are designed to stop damaging inflammation, and biologics work to interrupt the chain of events that leads to inflammation.

Newer biologics called anti-TNF agents - adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade) - prevent the production of an immunity protein that plays a role in inflammation.

Some of the key recommendations include:

  • Methotrexate or leflunomide therapy is recommended for most RA patients.
  • Anti-TNF agents etanercept, infliximab, or adalimumab along with methotrexate can be used in new or early RA cases with worsening and severe symptoms.
  • Doctors should not initiate or resume treatment with methotrexate, leflunomide, or biologics if RA patients have active bacterial infection, shingles (herpes-zoster), hepatitis B, hepatitis C and active or latent tuberculosis.
Doctors should not prescribe anti-TNF agents to patients with a history of heart failure, lymphoma or multiple sclerosis.

Source: Newswise
SRM
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest General Health News

Wild Poliovirus Resurfaces in Pakistan
The Pakistan Ministry has announced the commencement of a nationwide polio vaccination campaign beginning on October 2, aiming to immunize more children.
US Woman Loses All Limbs in Fish-Related Bacterial Outbreak
In a tragic incident, a woman in the US experienced the loss of all her limbs as a result of a bacterial outbreak linked to the consumption of contaminated fish.
NIH Launches the First In-Human Universal Flu Vaccine Trial
FluMos-v2, a unique universal influenza vaccine candidate, undergoing a phase 1 trial at NIH, increases recipients' immunity against many influenza viruses.
Global Polio Eradication Initiative Assesses Vaccination Strategies in Pakistan
In Pakistan, the polio campaign focuses on more than 270,000 children under the age of five years, residing in areas with insufficient vaccine coverage.
Diagnostic Errors: The Rocky Road to Life-threatening Health Complications
Dangers of Wrong Diagnosis: Diagnostic errors in healthcare can increase the risk of permanent disabilities and deaths.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Study Offers New Guidelines for Treating Rheumatoid Arthritis Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests